76 related articles for article (PubMed ID: 35952318)
1. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.
Diaz-Jimenez A; Ramos M; Helm B; Chocarro S; Frey DL; Agrawal S; Somogyi K; Klingmüller U; Lu J; Sotillo R
Drug Resist Updat; 2024 May; 74():101081. PubMed ID: 38521003
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.
Patel RA; Coleman I; Roudier MP; Konnick EQ; Hanratty B; Dumpit R; Lucas JM; Ang LS; Low JY; Tretiakova MS; Ha G; Lee JK; True LD; De Marzo AM; Nelson PS; Morrissey C; Pritchard CC; Haffner MC
Cancer Res Commun; 2022 May; 2(5):277-285. PubMed ID: 36337169
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent Yes1 kinase inhibitors using a library screening approach.
Patel PR; Sun H; Li SQ; Shen M; Khan J; Thomas CJ; Davis MI
Bioorg Med Chem Lett; 2013 Aug; 23(15):4398-403. PubMed ID: 23787099
[TBL] [Abstract][Full Text] [Related]
4. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer.
Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D
J Biol Chem; 2024 Apr; 300(6):107309. PubMed ID: 38657867
[TBL] [Abstract][Full Text] [Related]
5. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.
Blandin AF; Giglio R; Graham MS; Garcia G; Malinowski S; Woods JK; Ramkissoon S; Ramkissoon L; Dubois F; Schoolcraft K; Tsai J; Wang D; Jones R; Vogelzang J; Pelton K; Becker S; Watkinson F; Sinai C; Cohen EF; Booker MA; Tolstorukov MY; Haemels V; Goumnerova L; Wright K; Kieran M; Fehnel K; Reardon D; Tauziede-Espariat A; Lulla R; Carcamo B; Chaleff S; Charest A; De Smet F; Ligon AH; Dubuc A; Pages M; Varlet P; Wen PY; Alexander BM; Chi S; Alexandrescu S; Kittler R; Bachoo R; Bandopadhayay P; Beroukhim R; Ligon KL
Clin Cancer Res; 2023 Jul; 29(14):2651-2667. PubMed ID: 36780194
[TBL] [Abstract][Full Text] [Related]
6. Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
Moure CJ; Vara B; Cheng MM; Sondey C; Muise E; Park E; Vela Ramirez JE; Su D; D'Souza S; Yan Q; Yeung CS; Zhang M; Mansueto MS; Linn D; Buchanan M; Foti R; DiMauro E; Long B; Simov V; Barry ER
Mol Cancer Ther; 2024 May; ():OF1-OF14. PubMed ID: 38691847
[TBL] [Abstract][Full Text] [Related]
7. Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers.
Bilal E; Alexe G; Yao M; Cong L; Kulkarni A; Ginjala V; Toppmeyer D; Ganesan S; Bhanot G
Genes Cancer; 2010 Oct; 1(10):1063-73. PubMed ID: 21779430
[TBL] [Abstract][Full Text] [Related]
8. Genomic and experimental evidence that ALK
Inam H; Sokirniy I; Rao Y; Shah A; Naeemikia F; O'Brien E; Dong C; McCandlish DM; Pritchard JR
iScience; 2021 Nov; 24(11):103343. PubMed ID: 34825133
[TBL] [Abstract][Full Text] [Related]
9. Novel
Jiao Y; Liu M; Luo N; Guo H; Li J
JTO Clin Res Rep; 2020 Nov; 1(4):100079. PubMed ID: 34589958
[No Abstract] [Full Text] [Related]
10. Diffusion of molecular diagnostic lung cancer tests: a survey of german oncologists.
Steffen JA
J Pers Med; 2014 Mar; 4(1):102-14. PubMed ID: 25562146
[TBL] [Abstract][Full Text] [Related]
11. YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E; Garrido-Martin EM; Valencia K; Redrado M; Solorzano JL; Carias R; Echepare M; Exposito F; Serrano D; Ferrer I; Nunez-Buiza A; Garmendia I; García-Pedrero JM; Gurpide A; Paz-Ares L; Politi K; Montuenga LM; Calvo A
J Thorac Oncol; 2022 Dec; 17(12):1387-1403. PubMed ID: 35988891
[TBL] [Abstract][Full Text] [Related]
12. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers.
Liang H; Xu Y; Zhao J; Chen M; Wang M
Cancer Gene Ther; 2024 May; 31(5):652-666. PubMed ID: 38499647
[TBL] [Abstract][Full Text] [Related]
13. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
14. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E; Chun KS; Kim DH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338729
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.
Weidle UH; Birzele F
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):646-668. PubMed ID: 38035705
[TBL] [Abstract][Full Text] [Related]
16. A renaissance for YES in cancer.
Lapouge M; Meloche S
Oncogene; 2023 Nov; 42(46):3385-3393. PubMed ID: 37848624
[TBL] [Abstract][Full Text] [Related]
17. Circular RNAs: novel actors of Wnt signaling pathway in lung cancer progression.
Alimohammadi M; Gholinezhad Y; Mousavi V; Kahkesh S; Rezaee M; Yaghoobi A; Mafi A; Araghi M
EXCLI J; 2023; 22():645-669. PubMed ID: 37636026
[TBL] [Abstract][Full Text] [Related]
18. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
